argenx (ARGX) PT Raised to $131.00 at Wedbush
argenx (NASDAQ:ARGX) had its target price increased by research analysts at Wedbush from $130.00 to $131.00 in a research note issued on Tuesday, MarketBeat reports. The firm presently has an “outperform” rating on the stock. Wedbush’s target price would suggest a potential upside of 23.92% from the stock’s current price.
A number of other research firms have also issued reports on ARGX. Stifel Nicolaus started coverage on argenx in a research note on Thursday, September 13th. They issued a “buy” rating and a $139.00 target price on the stock. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $154.00 target price on shares of argenx in a research note on Monday, September 17th. Evercore ISI started coverage on argenx in a research note on Monday, October 15th. They issued an “outperform” rating and a $110.00 target price on the stock. JMP Securities upped their target price on argenx to $150.00 and gave the company an “outperform” rating in a research note on Monday, September 17th. Finally, SunTrust Banks upped their target price on argenx to $132.00 and gave the company an “in-line” rating in a research note on Tuesday, September 18th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $136.00.
ARGX opened at $105.71 on Tuesday. argenx has a 1-year low of $28.83 and a 1-year high of $111.43. The company has a market capitalization of $3.40 billion, a P/E ratio of -75.51 and a beta of 1.67.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Story: What is Depreciation?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.